1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1089/gte.2007.0050" target="_blank" rel="noreferrer noopener">http://doi.org/10.1089/gte.2007.0050</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
427-444
Issue
4
Volume
11
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Targeted Extended Cystic Fibrosis Mutation Testing On Known And At-risk Patients And Relatives
Publisher
An entity responsible for making the resource available
Genetic Testing
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-12
Subject
The topic of the resource
blood; cftr mutations; early-diagnosis; experience; Genetics & Heredity; immunoreactive trypsinogen; midlands; newborn; outcomes; Research & Experimental Medicine; vas-deferens; west; wisconsin
Creator
An entity primarily responsible for making the resource
Lebo R V; Omlor G J
Description
An account of the resource
This paper reports mathematically derived residual risks of being a carrier or being affected with cystic fibrosis following various screening scenarios to assist in interpreting test results and advising patients. While parental screening with 23 American College of Medical Genetics (ACMG) cystic fibrosis mutations defines the 64% of affected U. S. Caucasian fetuses with two detectable mutations, newborn screening for elevated immunoreactive trypsinogen (IRT) and sweat chloride identifies an additional 36% of affected newborns with zero or one detected mutation. The relatives of these affected newborns with less than two detectable mutations have higher posterior (after) 23 mutation-negative test risks of carrying undetected mutations. These calculations emphasize how knowledge of the mutations in the related affected patient substantially improves upon the quality of after-test advice to patients. Furthermore, negative tests of the partner without a family history and/or more extensive cystic fibrosis transmembrane conductance regulator (CFTR) gene testing also increases the likelihood that a negative report is truly negative. When a newborn patient with zero or one detected CFTR mutation has an inconclusive sweat test result, the sweat test should be repeated before ordering additional often unnecessary CFTR gene sequencing. Given the same composite mutation panel test accuracy, a higher proportion of reported test results would be correct during parental screening than when testing at-risk fetuses or symptomatic newborns. Prenatal and newborn screening would be enhanced substantially by medical professionals offering copies of all positive parental and newborn test reports to the parents to share with their relatives. These principles are likely to be applicable to other genetic diseases as the most common mutation frequencies are reported.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1089/gte.2007.0050" target="_blank" rel="noreferrer noopener">10.1089/gte.2007.0050</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article or Conference Abstract Publication
2007
Blood
cftr mutations
early-diagnosis
experience
Genetic Testing
Genetics & Heredity
immunoreactive trypsinogen
Journal Article or Conference Abstract Publication
Lebo R V
midlands
Newborn
Omlor G J
outcomes
Research & Experimental Medicine
vas-deferens
west
Wisconsin